S&CO Inc. Purchases Shares of 4,103 Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

S&CO Inc. bought a new position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) in the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor bought 4,103 shares of the pharmaceutical company’s stock, valued at approximately $1,989,000.

Several other large investors have also made changes to their positions in VRTX. GAMMA Investing LLC raised its stake in shares of Vertex Pharmaceuticals by 60,572.3% during the 1st quarter. GAMMA Investing LLC now owns 2,425,070 shares of the pharmaceutical company’s stock worth $1,175,722,000 after buying an additional 2,421,073 shares during the period. Capital World Investors raised its stake in shares of Vertex Pharmaceuticals by 5.7% during the 4th quarter. Capital World Investors now owns 28,325,695 shares of the pharmaceutical company’s stock worth $11,406,667,000 after buying an additional 1,514,993 shares during the period. Capital Research Global Investors raised its stake in shares of Vertex Pharmaceuticals by 15.8% during the 4th quarter. Capital Research Global Investors now owns 10,428,951 shares of the pharmaceutical company’s stock worth $4,199,713,000 after buying an additional 1,426,746 shares during the period. Edgewood Management LLC increased its position in shares of Vertex Pharmaceuticals by 91.2% during the fourth quarter. Edgewood Management LLC now owns 2,956,608 shares of the pharmaceutical company’s stock worth $1,190,626,000 after purchasing an additional 1,410,238 shares in the last quarter. Finally, Wellington Management Group LLP increased its position in shares of Vertex Pharmaceuticals by 23.3% during the fourth quarter. Wellington Management Group LLP now owns 5,916,084 shares of the pharmaceutical company’s stock worth $2,382,407,000 after purchasing an additional 1,117,214 shares in the last quarter. 90.96% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several analysts recently commented on VRTX shares. HC Wainwright reiterated a “buy” rating and set a $550.00 price target on shares of Vertex Pharmaceuticals in a research report on Monday, June 23rd. Morgan Stanley dropped their price target on Vertex Pharmaceuticals from $464.00 to $460.00 and set an “equal weight” rating for the company in a research report on Friday, June 20th. Royal Bank Of Canada set a $420.00 price target on Vertex Pharmaceuticals and gave the stock a “sector perform” rating in a research report on Tuesday, June 17th. Bank of America boosted their price target on Vertex Pharmaceuticals from $555.00 to $567.00 and gave the stock a “buy” rating in a research report on Monday, March 31st. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $535.00 target price on shares of Vertex Pharmaceuticals in a report on Tuesday, May 6th. Fourteen equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Vertex Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $512.30.

Vertex Pharmaceuticals Price Performance

VRTX stock opened at $460.83 on Tuesday. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.65 and a quick ratio of 2.29. The firm has a market capitalization of $118.34 billion, a P/E ratio of -117.56 and a beta of 0.41. The business’s 50-day moving average is $453.53 and its two-hundred day moving average is $465.77. Vertex Pharmaceuticals Incorporated has a 1 year low of $377.85 and a 1 year high of $519.88.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its quarterly earnings data on Monday, May 5th. The pharmaceutical company reported $4.06 EPS for the quarter, missing analysts’ consensus estimates of $4.29 by ($0.23). Vertex Pharmaceuticals had a negative net margin of 8.91% and a negative return on equity of 3.36%. The business had revenue of $2.77 billion during the quarter, compared to analysts’ expectations of $2.85 billion. During the same quarter in the previous year, the company posted $4.76 EPS. The company’s revenue was up 2.6% compared to the same quarter last year. Analysts anticipate that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current fiscal year.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.